Girish Chinnaswamy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Girish Chinnaswamy has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Maya Prasad
Division of Paediatric Oncology, Tata Memorial Centre, Mumbai, India
15 shared publications - Sridhar Epari
Department of Pathology (Including Molecular Pathology Division), Tata Memorial Hospital & ACTREC, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India
11 shared publications - Tejpal Gupta
Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India
11 shared publications - Abhishek Chatterjee
Department of Neurosurgery Tata Memorial Centre Homi Bhabha National Institute Dr. E. Borges Marg Mumbai India
9 shared publications - Adam L. Green
Morgan Adams Foundation Pediatric Brain Tumor Research Program, Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado
9 shared publications - Aimee Chan
Sunnybrook Health Sciences Centre 45 Division of Neurology, Department of Medicine , Toronto, Canada
9 shared publications
Latest Publications
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (7) , 313-322
Real World Outcomes of Metastatic Rhabdomyosarcoma in Children Treated With a Multimodal Protocol: A Single Center Experience
Background and Aims: Metastatic rhabdomyosarcoma (RMS) at diagnosis has poor outcomes. We audited these outcomes in children at a tertiary sarcoma unit. Methods: Children aged 15 years or younger with RMS at first diagnosis staged by FDG-PET CECT scan between January 2013 and December 2024 were retrospectively analyzed. Pulmonary, lymph node, and oligometastatic bone disease were treated with curative intent on a multimodal protocol comprising chemotherapy and local therapy to the primary and metastatic sites. Results: Of 126 patients, 19% had isolated pulmonary, 81% had extrapulmonary metastases, with bone marrow involvement in 3.1%. After neoadjuvant chemotherapy in 73 patients (treated with curative intent), 74% had complete response (CR), 19% partial response (PR), 4% stable disease, and 3% progression. Local therapy to the primary was given to 68 patients (radiotherapy: 70.5%, surgery+radiotherapy: 22.1%, surgery: 7.3%), and metastatic sites were treated in 61.8%. At a median follow-up of 11 months (IQR: 3.31, 20.8), 2-year EFS and OS probabilities were 30.2% (95% CI: 19.8-41.2) and 44.4% (95% CI: 32.5-55.6), respectively; survival did not differ by metastasis site. Complete response at primary (HR: 0.09, 95% CI: 0.30-0.29, P P =0.008), and bone marrow involvement (HR: 1.98, 95% CI: 1.01-3.91, P =0.050) affected EFS. Conclusions: Despite multimodal therapy, metastatic rhabdomyosarcoma continues to have poor outcomes. Tumor size ≥3.3 cm in oligometastatic disease and bone marrow involvement predicted poor prognosis, while complete primary site response after neoadjuvant chemotherapy was associated with improved survival.
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 48 (7) , 313-322
Real World Outcomes of Metastatic Rhabdomyosarcoma in Children Treated With a Multimodal Protocol: A Single Center Experience
Background and Aims: Metastatic rhabdomyosarcoma (RMS) at diagnosis has poor outcomes. We audited these outcomes in children at a tertiary sarcoma unit. Methods: Children aged 15 years or younger with RMS at first diagnosis staged by FDG-PET CECT scan between January 2013 and December 2024 were retrospectively analyzed. Pulmonary, lymph node, and oligometastatic bone disease were treated with curative intent on a multimodal protocol comprising chemotherapy and local therapy to the primary and metastatic sites. Results: Of 126 patients, 19% had isolated pulmonary, 81% had extrapulmonary metastases, with bone marrow involvement in 3.1%. After neoadjuvant chemotherapy in 73 patients (treated with curative intent), 74% had complete response (CR), 19% partial response (PR), 4% stable disease, and 3% progression. Local therapy to the primary was given to 68 patients (radiotherapy: 70.5%, surgery+radiotherapy: 22.1%, surgery: 7.3%), and metastatic sites were treated in 61.8%. At a median follow-up of 11 months (IQR: 3.31, 20.8), 2-year EFS and OS probabilities were 30.2% (95% CI: 19.8-41.2) and 44.4% (95% CI: 32.5-55.6), respectively; survival did not differ by metastasis site. Complete response at primary (HR: 0.09, 95% CI: 0.30-0.29, P P =0.008), and bone marrow involvement (HR: 1.98, 95% CI: 1.01-3.91, P =0.050) affected EFS. Conclusions: Despite multimodal therapy, metastatic rhabdomyosarcoma continues to have poor outcomes. Tumor size ≥3.3 cm in oligometastatic disease and bone marrow involvement predicted poor prognosis, while complete primary site response after neoadjuvant chemotherapy was associated with improved survival.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Map demonstrating the countries represented by contributing institutions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Map demonstrating the countries represented by contributing institutions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Long-term survivors ≥ 5 years (n = 12)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Long-term survivors ≥ 5 years (n = 12)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Patients with G34V mutation subtype (n = 9)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Patients with G34V mutation subtype (n = 9)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Initial chemotherapy combinations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Initial chemotherapy combinations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Kaplan-Meier survival plots demonstrating overall survival. (A). Initial chemotherapy (all ages): TMZ-based vs TMZ/CCNU. (B). Initial chemotherapy (under 18 years old): TMZ-based vs TMZ/CCNU. (C). Re-irradiation: yes vs no. (D). ATRX mutation: yes vs no. (E). PDGFRA amplification: yes vs no. (F) TP53 mutation: yes vs no. (G). PDGFRA mutation: yes vs no.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Kaplan-Meier survival plots demonstrating overall survival. (A). Initial chemotherapy (all ages): TMZ-based vs TMZ/CCNU. (B). Initial chemotherapy (under 18 years old): TMZ-based vs TMZ/CCNU. (C). Re-irradiation: yes vs no. (D). ATRX mutation: yes vs no. (E). PDGFRA amplification: yes vs no. (F) TP53 mutation: yes vs no. (G). PDGFRA mutation: yes vs no.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis.Experimental Design:This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets.Results:A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37–0.97).Conclusions:This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study
Purpose: Knowledge of prognostic factors and long-term survival in patients with diffuse hemispheric glioma, H3 G34–mutant (DHG, H3 G34), remains limited in this tumor with a poor prognosis.Experimental Design:This retrospective, multi-institutional study investigated prognostic variables for patients with DHG, H3 G34, and their association with progression-free survival (PFS) and overall survival (OS). Uni- and multivariable Cox proportional hazard models were applied with multiple imputed datasets.Results:A total of 153 patients (142 G34R, 9 G34V, 2 via DNA methylation) were included. The median age at diagnosis was 17 years (range, 2–45). Initial gross/near total resection (GTR/NTR) was achieved in 43% of patients. Radiation was given in 91% (85% focal irradiation), and initial chemotherapy was given in 87% [70% temozolomide-based (TMZ), 25% TMZ/lomustine, 5% non-TMZ]. Median OS was 24 months [interquartile range (IQR), 22–28] with a median PFS of 14 months (IQR, 12–19). Twelve patients (8%) were found to be long-term survivors (≥5 years). Exploratory multivariable analysis showed that adjuvant radiotherapy [HR, 0.076; 95% confidence interval (CI), 0.033–0.17] and achieving GTR/NTR compared with < NTR (HR, 0.51; 95% CI, 0.33–0.78) were associated with improved PFS. Multivariable analysis showed improved OS with increasing age at diagnosis (HR, 0.70; 95% CI, 0.57–0.87), initial radiotherapy (HR, 0.38; 95% CI, 0.15–0.96), and initial GTR/NTR compared with < NTR (HR, 0.60; 95% CI, 0.37–0.97).Conclusions:This cohort highlights prognostic factors for patients with DHG, H3 G34, and describes relapse patterns and therapy approaches. Clinical trials and prospective registries are needed to improve outcomes.
- Open Access
- 18 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (Suppl 2) , ii71-ii78
Enabling Precision Medicine and Targeted Therapeutics in LMIC
Childhood brain tumors are the leading cause of cancer-related morbidity and mortality in children worldwide. Delayed diagnosis, inadequate diagnostic and treatment infrastructure are significant barriers to an optimal outcome in low- and middle-income countries (LMICs), where 80% of children with cancer live. Pediatric neuro-oncology has undergone a transformation with recent developments in molecular diagnosticsand emergence of targeted therapies. However, the implementation of precision medicine in LMICs is challenging in view of high costs, lack of trained personnel, and restricted access to essential medications. Targeted therapies such as MEK, BRAF & NTRK inhibitors have demonstrated promising efficacy with improved toxicity profiles, inpediatric brain tumors with actionable mutations. Despite their potential, availability in LMICs is largely restricted to compassionate use programs and select clinical trials. Encouraging results albeit from few institutions in LMICs, have demonstrated that targeted therapies have significant impact on quality of life (QOL), in addition to comparable efficacy. Sustainable integration of precision medicine in LMICs requires improved access to affordable molecular diagnostics, inclusion of more targeted drugs in the WHO Essential Medicines List, and participation in international clinical trials. Collaborative models—such as twinning programs, telemedicine, regional reference laboratories, and capacity-building initiatives—can support implementation. Global programs like the WHO Global Initiative for Childhood Cancer and the ATOM Coalition play a vital role in improving drug access and policy advocacy. Enabling precision medicine in LMICs calls for a coordinated multi-stakeholder approach including integration into the national cancer care policy, and is critical to bridging the survival gap and ensuring equitable outcomes for children with brain tumors globally.
- 18 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (Suppl 2) , ii71-ii78
Open AccessEnabling Precision Medicine and Targeted Therapeutics in LMIC
Childhood brain tumors are the leading cause of cancer-related morbidity and mortality in children worldwide. Delayed diagnosis, inadequate diagnostic and treatment infrastructure are significant barriers to an optimal outcome in low- and middle-income countries (LMICs), where 80% of children with cancer live. Pediatric neuro-oncology has undergone a transformation with recent developments in molecular diagnosticsand emergence of targeted therapies. However, the implementation of precision medicine in LMICs is challenging in view of high costs, lack of trained personnel, and restricted access to essential medications. Targeted therapies such as MEK, BRAF & NTRK inhibitors have demonstrated promising efficacy with improved toxicity profiles, inpediatric brain tumors with actionable mutations. Despite their potential, availability in LMICs is largely restricted to compassionate use programs and select clinical trials. Encouraging results albeit from few institutions in LMICs, have demonstrated that targeted therapies have significant impact on quality of life (QOL), in addition to comparable efficacy. Sustainable integration of precision medicine in LMICs requires improved access to affordable molecular diagnostics, inclusion of more targeted drugs in the WHO Essential Medicines List, and participation in international clinical trials. Collaborative models—such as twinning programs, telemedicine, regional reference laboratories, and capacity-building initiatives—can support implementation. Global programs like the WHO Global Initiative for Childhood Cancer and the ATOM Coalition play a vital role in improving drug access and policy advocacy. Enabling precision medicine in LMICs calls for a coordinated multi-stakeholder approach including integration into the national cancer care policy, and is critical to bridging the survival gap and ensuring equitable outcomes for children with brain tumors globally.